BiologicalDrug
Allogeneic Adipose-derived Mesenchymal Stem Cells clinical trials
- studies test it
- 22
- open now
- 3
- in phase 3
- 2
- first study started
- 2012
Keep track of what changes. Save the Allogeneic Adipose-derived Mesenchymal Stem Cells studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 14
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 6
Anterogen Co., Ltd. (8) · Sorrento Therapeutics, Inc. (6) · Stempeutics Research Pvt Ltd (2) · Mya Schiess (1) · LaTonya J. Hickson (1) · Rigshospitalet, Denmark (1) · The University of Texas Health Science Center, Houston (1) · Mayo Clinic (1)
Studies
Open first, then newest update. How each study uses Allogeneic Adipose-derived Mesenchymal Stem Cells is read from its arms, and is right about nine times in ten.
Testing it · 22
- Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing CraniotomyRecruitingPhase 1Mayo ClinicNCT05789394Written as Allogeneic Adipose-derived Mesenchymal Stem Cells
- Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years OldRecruitingPhase 1Instituto de Investigación Sanitaria de la Fundación Jiménez DíazNCT06738576Written as allogeneic mesenchymal stem cells
- Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot UlcersRecruitingPhase 2Anterogen Co., Ltd.NCT04497805Written as ALLO-ASC-SHEET
- Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's DiseaseCompletedPhase 2Mya SchiessNCT04506073Written as Mesenchymal Stem Cells
- Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.CompletedPhase 3Anterogen Co., Ltd.NCT04569409Written as ALLO-ASC-DFU
- Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot UlcersCompletedPhase 2Anterogen Co., Ltd.NCT03754465Written as ALLO-ASC-DFU
- Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney DiseaseCompletedPhase 1LaTonya J. HicksonNCT05362786Written as Allogeneic adipose-derived mesenchymal stem cells (MSC)
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04992247Written as COVI-MSC
- Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.CompletedPhase 3Anterogen Co., Ltd.NCT03370874Written as ALLO-ASC-DFU
- A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury SubjectsCompletedPhase 2Anterogen Co., Ltd.NCT02619851Written as ALLO-ASC-DFU
- Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's SyndromeCompletedPhase 2Rigshospitalet, DenmarkNCT04615455Written as ASCs
- Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory DistressTerminatedPhase 2Sorrento Therapeutics, Inc.NCT04903327Written as COVI-MSC
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory DistressStatus unknownPhase 2Sorrento Therapeutics, Inc.NCT04905836Written as COVI-MSC
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress SyndromeWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04909879Written as COVI-MSC
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04909892Written as COVI-MSC
- Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory DistressWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04728698Written as COVI-MSC
- Stem Cell Injection in Cancer SurvivorsCompletedPhase 1The University of Texas Health Science Center, HoustonNCT02509156Written as Allo-MSCs
- Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot UlcersCompletedPhase 2Anterogen Co., Ltd.NCT02619877Written as ALLO-ASC-DFU
- Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver CirrhosisCompletedPhase 2Stempeutics Research Pvt LtdNCT01591200Written as Allogeneic Mesenchymal Stem Cells
- A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers DiseaseCompletedPhase 2Stempeutics Research Pvt LtdNCT01484574Written as Allogeneic Mesenchymal Stem Cells
See all 22 studies that test Allogeneic Adipose-derived Mesenchymal Stem Cells →